MVF delivers 1H26 Underlying NPAT of $10.4m
| Stock | Monash Ivf Group Ltd (MVF.ASX) |
|---|---|
| Release Time | 26 Feb 2026, 9:15 a.m. |
| Price Sensitive | Yes |
Monash IVF Group delivers 1H26 Underlying NPAT of $10.4m
- Maintained ART Sector leading clinical pregnancy rates
- Performed 5,163 stimulated cycles in Australia, holding 19% market share
- Attracted 4 new fertility specialists and retained 168 medical specialists
Monash IVF Group Limited (ASX:MVF) has announced its financial results for the first half of fiscal year 2026 (1H26). The company delivered 1H26 revenue of $137.9 million, a 1.8% decrease compared to 1H25. Underlying NPAT for 1H26 was $10.4 million, in line with the guidance provided in November 2025. The company maintained its ART Sector leading clinical pregnancy rates, with a further 0.6% increase in clinical pregnancy rate per embryo transferred (women aged <43 years) to 40.7% in January to September 2025, up from 32.6% in CY18. Monash IVF performed 5,163 stimulated cycles in Australia and maintained its position as the #2 largest IVF provider in Australia, holding 19% of market share. The company attracted 4 new fertility specialists and retained 168 medical specialists, as well as 172 scientists across the Group. Domestic IVF new patient registrations during 1H26 were stable and consistent with 2H25. The major infrastructure transformation is almost complete, with the new Brisbane clinic scheduled for completion in Q4FY26. The company's 1H26 financial outcomes included a decrease in Australian Stimulated Cycles by 11.7% compared to the prior corresponding period, while International Stimulated Cycles increased by 6.9%. Ultrasound scans decreased by 3.1% compared to the prior corresponding period. The company is expecting FY26 Underlying NPAT of $20.0 million, consistent with the profit guidance announced in November 2025.
The company is expecting FY26 Underlying NPAT of $20.0 million, capital expenditure for the full year of $16 to $17 million, and net debt at 30 June 2026 of approximately $95 million with a net leverage ratio of 2.0x.
The company's new CEO and Managing Director, Dr. Victoria Atkinson, has stated that her immediate focus is on clinical and operational excellence, supporting the clinicians, and ensuring consistent, high-quality patient experience across the network, while remaining committed to executing the company's strategy and delivering sustainable value for shareholders.